TumorSight Viz
K243189SimBioSys, Inc. · cleared 2024-10-25 · product code QIH · Radiology
Premarket evidence — what FDA accepted
source quote (p.5)
“The TumorSight system consists of proprietary software developed by SimBioSys, Inc. hosted on a cloud-based platform and accessed on an off-the-shelf computer.”
source quote (p.8)
“The measurements generated from the device result directly from the segmentation methodology and are an inferred reflection of the performance of the deep learning algorithm.”
Validation studies (1)
Reader study (MRMC)
n=217 cases · 7 site(s)
endpoints: Tumor Volume; Tumor-to-breast volume ratio; Tumor longest dimension; Tumor-to-nipple distance; Tumor-to-skin distance; Tumor-to-chest distance; Tumor center of mass; Volumetric Dice; Surface Dice
standards: ISO 14971
Reported performance (2 observations)
source quote (p.9)
“0.75 ± 0.24”
source quote (p.9)
“0.88±0.24”
Each value carries its own analysis unit and task — never compare or pool across devices. Source: 510(k) summary PDF.
Predicate network
Postmarket — what happened after clearance
- re_clearance
The FDA AI/ML device list shows a newer 510(k) K251766 (decision 2025-07-08) from SimBioSys, Inc. for a matching device line ("TumorSight Viz") — a new clearance for the same line is a change event.
first seen 2026-07-08 · k_number:K251766
Recall and MAUDE counts are product-code-level (reports aren't reliably attributable to one device). Signals are descriptive observables with sources — never a judgment that the device is unsafe or drifting. Snapshot 2026-07-08.
Reimbursement — how devices like this got paid
Not yet tracked — no payment pathway indexed for this clearance (the reimbursement corpus is a growing seed set).